The researchers (IMAGE)
Caption
The research groups led by Professor Martin Roelsgaard Jakobsen (right) and Associate Professor Rasmus Bak (left) have now clarified the key conditions needed to develop large numbers of the rare immune cells in a laboratory. Together with former postdoc Anders Laustsen, they have channeled the research into the newly started company UNIKUM Therapeutics, which aims to use pDCs for clinical therapeutic use. Photo: Simon Byrial Fischel
Credit
Photo: Simon Byrial Fischel
Usage Restrictions
No restrictions
License
Original content